Takeda Pharmaceutical Company Limited Stock Deutsche Boerse AG
Stocks
TKDA
US8740602052
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Tradegate
09:53:01 02/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 15.65 EUR | +1.62% |
|
0.00% | +18.18% |
| 08-31 | Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House | MT |
| 08-31 | Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House | MT |
| Market Cap | 9,333B 58.3B 50.29B 47.31B 43.1B 81.05B 5,533B 81.48B 559B 218B 2,815B 219B 214B | P/E 2027 * |
46.6x | P/E 2028 * | 29.9x |
|---|---|---|---|---|---|
| Enterprise Value | 13,240B 82.71B 71.34B 67.11B 61.14B 115B 7,849B 116B 793B 309B 3,993B 311B 304B | EV / Sales 2027 * |
2.82x | EV / Sales 2028 * | 2.73x |
| Free-Float |
99.26% | Yield 2027 * |
3.5% | Yield 2028 * | 3.56% |
Last Transcript : Takeda Pharmaceutical Company Limited
| 1 day | +1.62% | ||
| Current month | +1.30% | ||
| 1 month | +6.12% | ||
| 3 months | +17.29% | ||
| 6 months | -1.27% | ||
| Current year | +18.18% |
| 1 week | 15.3 |  | 15.6 |
| 1 month | 14.2 | | 15.6 |
| Current year | 12.8 | | 16.1 |
| 1 year | 11.3 | | 16.1 |
| 3 years | 11.3 | | 16.1 |
| 5 years | 11.3 | | 16.1 |
| 10 years | 11.3 | | 19.27 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.62% | 0.00% | - | - | 58.3B | |
| +0.28% | -5.97% | +58.34% | +108.22% | 1,034B | |
| +2.01% | -0.71% | +53.07% | +68.99% | 654B | |
| +1.39% | -2.18% | +23.57% | +75.43% | 459B | |
| +0.53% | -5.29% | +33.13% | +35.38% | 343B | |
| -0.63% | +2.36% | +28.64% | +46.22% | 307B | |
| -0.69% | -3.14% | -0.45% | +10.85% | 251B | |
| +1.92% | -0.93% | +52.28% | +70.67% | 237B | |
| -0.20% | -3.67% | -18.05% | -55.18% | 202B | |
| +2.45% | +0.77% | +32.71% | +95.59% | 186B | |
| Average | +1.01% | -2.88% | +29.25% | +50.68% | 407.95B | |
| Weighted average by Cap. | +1.18% | -3.31% | +38.32% | +66.47% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,695B 29.33B 25.3B 23.8B 21.68B 40.77B 2,783B 40.99B 281B 109B 1,416B 110B 108B | 4,773B 29.82B 25.72B 24.19B 22.04B 41.45B 2,830B 41.67B 286B 111B 1,439B 112B 110B |
| Net income | 195B 1.22B 1.05B 989M 901M 1.69B 116B 1.7B 11.69B 4.55B 58.83B 4.58B 4.48B | 318B 1.99B 1.72B 1.61B 1.47B 2.77B 189B 2.78B 19.08B 7.43B 96.05B 7.47B 7.31B |
| Net Debt | 3,907B 24.4B 21.05B 19.8B 18.04B 33.92B 2,316B 34.11B 234B 91.11B 1,178B 91.62B 89.64B | 3,703B 23.13B 19.96B 18.77B 17.1B 32.16B 2,196B 32.33B 222B 86.37B 1,117B 86.86B 84.97B |
| Date | Price | Change |
|---|---|---|
| 02/09/26 | €15.60 | +1.30% |
| 01/09/26 | €15.40 | 0.00% |
| 31/08/26 | €15.40 | +0.65% |
| 28/08/26 | €15.30 | -1.29% |
| 27/08/26 | €15.50 | -0.64% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TKDA Stock
Select your edition
All financial news and data tailored to specific country editions
